Alfresa Pharma has found its niche partnering with foreign companies and R&D
based organizations. We offer particular advantage in the therapeutic areas of
neuropsychiatric disorders, allergy, and gastro-intestinal diseases.
Our Anafranil® (tricyclic antidepressant) is Japan’s most often prescribed treatment for depression. Modafinil (Modiodal® ), developed for Japan in affiliation with Cephalon, U.S.A., is a drug for sleep disorders such as narcolepsy. Nipolazin® is an antihistamine with a high safety profile used for the treatment of allergic diseases. EPL promotes the resolution of neutral lipid levels and is well known for the treatment of fatty liver diseases such as non-alcoholic steatohepatitis(NASH).
Competent in the development, manufacture and marketing of pharmaceuticals our partnerships realize the launch of new drugs into Japan.
Alfresa Pharma's Modafinil (Modiodal® ), indicated for the treatment of sleep disorders such as narcolepsy, has been developed for an orphan indication in Japan. Since 2007, Alfresa Pharma manufactures and markets Modafinil and is currently pressing forward with research into expanded indications for sleep apnea syndrome (SAS) and other disorders.
